Citizens Maintains Market Outperform on LeMaitre Vascular, Lowers Price Target to $110
Benzinga Newsdesk 22 hours ago
Analyst RatingsNewsPrice Target
Citizens analyst Daniel Stauder maintains LeMaitre Vascular (NASDAQ:LMAT) with a Market Outperform and lowers the price target from $127 to $110.
Citizens analyst Daniel Stauder maintains LeMaitre Vascular (NASDAQ:LMAT) with a Market Outperform and lowers the price target from $127 to $110.